Sign In
Buy SRPT
$16.24
-0.0100 (-0.0615%)
At Close: Jun 03, 2026
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences
11:39am, Wednesday, 18'th Jun 2025
In another tragic incident, Sarepta Therapeutics NASDAQ: SRPT saw a second death in connection with its Duchenne muscular dystrophy (DMD) treatment ELEVIDYS. The patient passed away due to acute live
SRPT NOTICE: Did Sarepta Therapeutics, Inc. Mislead Investors about the Safety of Elevidys? Contact BFA Law if You Lost Money (NASDAQ:SRPT)
08:38am, Wednesday, 18'th Jun 2025
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ: SRPT) for potential violations of
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
07:08pm, Tuesday, 17'th Jun 2025
NEW YORK , June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are
NEW YORK--(BUSINESS WIRE)---- $SRPT #Attorney--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ: SRPT) for potential violations
SRPT Stock: What's Happening With Sarepta Therapeutics?
07:40am, Tuesday, 17'th Jun 2025
Sarepta Therapeutics (NASDAQ: SRPT) suffered a devastating blow on Monday, June 16 when its stock plummeted 42% following news of a second patient death linked to its Duchenne muscular dystrophy gene
Mizuho's Jared Holz on what is next for Sarepta after second death connected to gene therapy
06:16pm, Monday, 16'th Jun 2025
Jared Holz, Mizuho, joins 'Fast Money' to talk the fallout for Sarepta after another death related to its muscular dystrophy gene therapy.
Down To Levels Not Seen Since 2016: Initiating Sarepta With A Buy
12:14pm, Monday, 16'th Jun 2025
Sarepta Therapeutics, Inc. plunged over 47% after a second ELEVIDYS-related patient death, raising serious safety concerns and leading to trial suspensions. Despite the negative headlines and slashed
PHILADELPHIA, PA / ACCESS Newswire / June 16, 2025 / Kehoe Law Firm, P.C. is investigating potential violations of federal securities laws and claims on behalf of investors of Sarepta Therapeutics, In
Sarepta's gene therapy medicine kills patient, CEO suspends full year guidance
11:11am, Monday, 16'th Jun 2025
CNBC's Angelica Peebles reports on the latest news regarding Sarepta.
SRPT Down Near 9-Year Low, CSCO Upgrade, ROKU Using AMZN Ads
10:30am, Monday, 16'th Jun 2025
Sarepta Therapeutics (SRPT) sold off more than 40% after suspending its Elevidys Duchenne muscular dystrophy drug, which was linked to two fatal liver failure cases. Diane King Hall break takes a clos
SRPT Plummets on Second Patient Death After DMD Gene Therapy Infusion
09:45am, Monday, 16'th Jun 2025
Sarepta's shares sink as second Elevidys-linked death triggers safety concerns, dosing halts and trial pauses.
Sarepta Therapeutics stock drops following second death linked to gene therapy Elevidys
09:44am, Monday, 16'th Jun 2025
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares plunged almost 45% after the company disclosed the death of a second patient from acute liver failure linked with its experimental gene therapy Elevidys f
Sarepta Therapeutics' Elevidys Liver Deaths Trigger Selloff, A Contrarian Opportunity
09:00am, Monday, 16'th Jun 2025
Sarepta's stock has plunged due to safety concerns with ELEVIDYS, including two deaths in non-ambulatory DMD patients and regulatory uncertainty. Despite these setbacks, ELEVIDYS remains effective for
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session
08:38am, Monday, 16'th Jun 2025
U.S. stock futures were higher this morning, with the Dow futures gaining more than 150 points on Monday.
Sarepta Stock Crashes After Death of Second Patient Receiving Its Gene Therapy
06:18am, Monday, 16'th Jun 2025
A second patient receiving its experimental gene therapy Elevidys has died from liver failure, raising serious questions on the drug's outlook.
